Imipenem/Cilastatina Kabi

Imipenem/Cilastatin, the active ingredient in Imipenem/Cilastatin Kabi, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections, including intra‑abdominal, urinary, skin, and respiratory infections, in hospitalized adult patients. GNH USA supplies Imipenem/Cilastatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/Cilastatin is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems. - Complicated intra‑abdominal infections: provides rapid bacterial eradication in the peritoneal cavity. - Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis and cystitis. - Complicated skin and soft tissue infections: clears mixed Gram‑positive and Gram‑negative organisms. - Hospital‑acquired and ventilator‑associated pneumonia: penetrates lung tissue to treat resistant pneumonia pathogens. - Severe sepsis: offers bactericidal activity against a wide range of pathogens in systemic infection.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional emesis after infusion. - Headache: transient cranial discomfort. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile‑associated diarrhea: colitis due to disruption of normal flora. - Neutropenia: marked reduction in neutrophil count. - Thrombocytopenia: decreased platelet levels. - Renal impairment: worsening kidney function in susceptible individuals.

Careful assessment and monitoring are required when using this intravenous carbapenem. - Assess renal function: dose adjustment may be needed in renal insufficiency. - Monitor for seizures: avoid in patients with a history of CNS disorders. - Evaluate hypersensitivity: discontinue if signs of an allergic reaction appear. - Use caution with concomitant nephrotoxic agents: increased risk of kidney injury. - Adjust dose in severe renal impairment: follow prescriber guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Imipenem/Cilastatin can alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough. - Other carbapenems: concurrent use may increase toxicity without added benefit. - High‑dose aminoglycosides: combined nephrotoxic potential.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance renal electrolyte loss; monitor electrolytes. - Warfarin: possible alteration of INR; check coagulation status regularly. - Oral contraceptives: reduced efficacy; advise alternative contraception.